Cooperated Commercial Products
| Number | Product | CAS | Indication | Qualification | |
|---|---|---|---|---|---|
| 1 | Ursodeoxycholic acid | 128-13-2 | Biliary Cirrhosis/Gallbladder Stones | WC / DMF |
|
| 2 | Diosmin | 520-27-4 | Chronic Venous Insufficiency/Hemorrhoids | WC / DMF / CEP |
|
| 3 | Troxerutin | 7085-55-4 | Cardiovascular Diseases | WC / DMF / CEP |
|
| 4 | Rutin | 153-18-4 | Hemorrhage | WC / DMF / CEP |
|
| 5 | Nilotinib | 183321-74-6 | Ph+ CML | DMF / GMP |
|
| 6 | Methotrexate | 59-05-2 | Neoplastic Diseases/Psoriasis/Rheumatoid Arthritis | WC / DMF |
|
| 7 | Irinotecan | 97682-44-5 | Advanced Colorectal Cancer | WC / DMF |
|
| 8 | Letrozole | 112809-51-5 | Breast Cancer | WC / DMF |
|
| 9 | Anastrozole | 120511-73-1 | Breast Cancer | WC / DMF |
|
| 10 | Hesperidin | 520-26-3 | Cardiovascular Diseases | DMF / GMP |
|
| 11 | Ferric Carboxymaltose | 9007-72-1 | Iron Supplement | WC / DMF |
|
| 12 | Imatinib | 152459-95-5 | Ph+ CML | DMF / GMP |
|
| 13 | Gefitinib | 184475-35-2 | EGFR-mutated non-small Cell lung cancer | DMF / GMP |
|
| 14 | Polysulfated Glycosaminoglycan | Arthriti | DMF（2025 Q4） |
|
